Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Its pipeline includes tobevibart, an investigational antibody, and elebsiran, an investigational small interfering RNA, being studied in combination for chronic hepatitis… From the company’s description.
Over the twelve months to Sep 30, 2026, Vir Biotechnology, Inc. reported revenue of $302.80M, up 1696.0% from a year earlier, and a net loss of $184.79M. Its operating margin was −69.8%, and operations used $141.02M in cash. In fiscal 2025, it reported revenue of $68.56M, down 7.6% from fiscal 2024, and a net loss of $437.99M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Vir Biotechnology, Inc. does
In the company’s own words
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Its pipeline includes tobevibart, an investigational antibody, and elebsiran, an investigational small interfering RNA, being studied in combination for chronic hepatitis delta, as well as broadly neutralizing antibodies for HIV and dual-masked T-cell engagers for solid tumors. The company’s three clinical-stage T-cell engagers target PSMA, HER2 and EGFR, and are designed to activate preferentially in the tumor environment. Vir uses antibody discovery and protein engineering, its dAIsY artificial-intelligence platform, and the PRO-XTEN masking technology to discover and develop candidates. Its research also includes preclinical candidates for solid tumors and antibodies against influenza and coronaviruses available for external partnerships. Vir has a history of developing antibody medicines, including sotrovimab for COVID-19 and ansuvimab for Ebola, which is marketed by Ridgeback Biotherapeutics. For fiscal 2025, its business is focused on research and development rather than commercial product sales. Its website is https://www.vir.bio.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- SAN FRANCISCO, CA
- Fiscal year end
- December
- CIK
- 1706431
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Vir Biotechnology, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Vir Biotechnology, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Vir Biotechnology, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Vir Biotechnology, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Vir Biotechnology, Inc.'s last four quarterly filings that the numbers alone won't show?”